John Townsend's most recent trade in Unicycive Therapeutics Inc was a trade of 169,500 Restricted Stock Unit done . Disclosure was reported to the exchange on May 14, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Unicycive Therapeutics Inc | John W. Townsend | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 169,500 | 169,500 | - | - | Restricted Stock Unit | |
| Unicycive Therapeutics Inc | John W. Townsend | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2026 | 169,500 | 169,500 | - | - | Restricted Stock Unit | |
| Ribbon Communications Inc | John Townsend | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 25,641 | 76,923 | - | - | Restricted Stock Units (RSUs) | |
| Ribbon Communications Inc | John Townsend | EVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 25,641 | 103,398 (0%) | 0% | - | Common Stock | |
| Ribbon Communications Inc | John Townsend | EVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.48 per share. | 15 Apr 2026 | 10,089 | 93,309 (0%) | 0% | 2.5 | 25,021 | Common Stock |
| Ribbon Communications Inc | John Townsend | EVP, Chief Financial Officer | 15 Oct 2025 | 128,205 | 128,205 (0%) | 0% | - | Common Stock | ||
| Ribbon Communications Inc | John Townsend | EVP, Chief Financial Officer | 15 Oct 2025 | 128,205 | 102,564 | - | - | Restricted Stock Units (RSUs) | ||
| Ribbon Communications Inc | John Townsend | EVP, Chief Financial Officer | 15 Oct 2025 | 50,448 | 77,757 (0%) | 0% | 3.8 | 192,207 | Common Stock | |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2025 | 10,000 | 101,557 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2024 | 40,256 | 915,565 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 228,119 | 875,309 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Aug 2023 | 570,329 | 647,190 | - | - | Stock Options | |
| Unicycive Therapeutics Inc | John W. Townsend | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2022 | 35,000 | 76,861 | - | - | Stock Options |